WARPTECHNEWS · LAB

Home AI Business Tech Archive

FDA approves Orzeyful for type 1 narcolepsy in adults — Warptech Lab News

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

FDA approves Orzeyful for type 1 narcolepsy in adults

The FDA has approved oveporexton for the treatment of narcolepsy type 1 in adults, according to officials with Takeda, the drug’s developer. Oveporexton (Orzeyful, Takeda), an oral orexin receptor 2 agonist, is the first medicine indicated in the U.S. to treat narcolepsy type 1 (NT1) holistically instead of treating individual symptoms, Takeda officials said in a press release.

venerdì 7 agosto 2026 New tab

741 words~3 min read

August 07, 2026

3 min read

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Other newsrooms on this story

· 10 sources

Full timeline →

medpagetoday.com·Aug 6, 2026 · 23 g fa
FDA Approves First-in-Class Narcolepsy Drug
morningstar.com·Aug 6, 2026 · 24 g fa
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
upi.com·Aug 6, 2026 · 24 g fa
FDA approves new drug for narcolepsy type 1 symptoms - UPI.com
fiercepharma.com·Aug 6, 2026 · 23 g fa
Takeda gains FDA nod for first-in-class narcolepsy treatment Orzeyful
endpoints.news·Aug 5, 2026 · 24 g fa
Let the orexin market begin: Takeda snags FDA approval for narcolepsy type 1 drug
biopharmadive.com·Aug 6, 2026 · 24 g fa
Takeda approval ushers in new wave of sleep drugs
statnews.com·Aug 5, 2026 · 24 g fa
Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments
adnkronos.com·Aug 7, 2026 · 23 g fa
Svolta contro la narcolessia, negli Usa la prima cura che agisce sulla causa della malattia
caixinglobal.com·Aug 5, 2026 · 25 g fa
China Beats U.S. in Approving Takeda’s Breakthrough Narcolepsy Drug
fiercepharma.com·Aug 7, 2026 · 23 g fa
Fierce Pharma Asia—Takeda’s historic narcolepsy nod; Daiichi’s accounting error; Astellas’ revenue beat

Related reading

medpagetoday.com

FDA Approves First-in-Class Narcolepsy Drug

Oveporexton treats more than symptoms, restores orexin signaling

medpagetoday.com·23 g fa

morningstar.com

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine…

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

morningstar.com·24 g fa

morningstar.com

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to…

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

morningstar.com·6 g fa

FDA approves new drug for narcolepsy type 1 symptoms - UPI.com

The U.S. Food and Drug Administration on Wednesday approved the first drug to treat a "full range" of narcolepsy type 1 symptoms…

upi.com·24 g fa

fiercepharma.com

Takeda gains FDA nod for first-in-class narcolepsy treatment Orzeyful

After coming up short in trials with two orexin type 2 receptor (OX2R) selective agonists, Takeda has scored with oveporexton,

fiercepharma.com·23 g fa

Let the orexin market begin: Takeda snags FDA approval for narcolepsy type 1…

Takeda's Orzeyful wins FDA approval as the first full-symptom narcolepsy type 1 drug, kicking off an orexin agonist race with…

endpoints.news·24 g fa